Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

A Case of Adult B Lymphoblastic Leukemia with ider(9)(q10)t(9;22)(q34;q11.2) and der(19)t(1;19)(q23;p13.3)

  • Jung, Soon-Il (Department of Laboratory Medicine, Yeungnam University College of Medicine) ;
  • Cho, Hee-Soon (Department of Laboratory Medicine, Yeungnam University College of Medicine) ;
  • Lee, Chae-Hoon (Department of Laboratory Medicine, Yeungnam University College of Medicine) ;
  • Jung, Bo-Chan (Department of Laboratory Medicine, Gumi CHA General Hospital, Pochon CHA University College of Medicine)
  • Received : 2010.03.18
  • Accepted : 2010.10.13
  • Published : 2010.12.01
⟨ Previous Next ⟩

Abstract

In B lymphoblastic leukemia/lymphoma (B-ALL/LBL), t(9;22)(q34;q11.2) and t(1;19)(q23;p13.3) are recurrent cytogenetic abnormalities. The concurrent occurrence of both abnormalities is very rare, and only 3 cases have been previously reported. Here, we report a case of adult B-ALL with ider(9)(q10)t(9;22)(q34;q11.2) and der(19)t(1;19)(q23;p13.3). A literature review revealed that ider(9) (q10)t(9;22) is a rare variant of t(9;22) with a deletion of the short arm of chromosome 9. Fifteen cases of ider(9)(q10)t(9;22) have been reported. This abnormality is specific to precursor B-lymphoid neoplasms, such as B-ALL or B-lymphoid blast phase of CML, and is associated with disease progression or short survival. The cytogenetic abnormality t(1;19) is also specific to B-ALL. In most instances of t(1;19), TCF3 is fused to PBX1; however, a few cases have identical translocations but no TCF3-PBX1 fusion, as was observed in our patient. We describe the first case of ider(9)(q10)t(9;22) in combination with TCF3-PBX1 negative t(1;19). The patient underwent imatinib therapy in addition to intensive chemotherapy, but failed to achieve remission.

Keywords

Acknowledgement

Supported by : Yeungnam University

References

  1. Borowitz MJ and Chan JKC. B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities. In: Swerdlow SH, Harris NL, et al. eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer, 2008:171-5.
  2. Mitelman F, Johansson B, Mertens F (Eds.). Mitelman database of chromosome aberrations and gene fusions in cancer (2010). http://cgap.nci.nih.gov/Chromosomes/Mitelman (Updated on Feb 2010).
  3. Sessarego M, Defferrari R, Fugazza G, Comelli A, Salvidio E, Ajmar F. Involvement of the short arm of the derivative chromosome 9 in Philadelphia-positive acute lymphoblastic leukemia. Cancer Genet Cytogenet 1991;52:43-9. https://doi.org/10.1016/0165-4608(91)90052-V
  4. Heerema NA, Palmer CG, Weetman R, Bertolone S. Cytogenetic analysis in relapsed childhood acute lymphoblastic leukemia. Leukemia 1992;6:185-92.
  5. Dierlamm J, Michaux L, Kroger N, Wlodarska I, Martiat P, Zeller W, et al. ider(9)(q10)t(9;22)(q34;q11) is a recurrent chromosomal abnormality in acute lymphoblastic leukemia and lymphatic blastic phase of chronic myelogenous leukemia. Cancer Genet Cytogenet 1996;89:109-13. https://doi.org/10.1016/0165-4608(95)00342-8
  6. Rieder H, Ludwig WD, Gassmann W, Maurer J, Janssen JW, Gokbuget N, et al. Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia. Br J Haematol 1996;95:678-91. https://doi.org/10.1046/j.1365-2141.1996.d01-1968.x
  7. Uckun FM, Nachman JB, Sather HN, Sensel MG, Kraft P, Steinherz PG, et al. Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: a report from the Children's Cancer Group. Cancer 1998;83:2030-9. https://doi.org/10.1002/(SICI)1097-0142(19981101)83:9<2030::AID-CNCR21>3.0.CO;2-Q
  8. Kansal R, Deeb G, Barcos M, Wetzler M, Brecher ML, Block AW, et al. Precursor B lymphoblastic leukemia with surface light chain immunoglobulin restriction: a report of 15 patients. Am J Clin Pathol 2004;121:512-25. https://doi.org/10.1309/WTXCQ5NRACVXTYBY
  9. Preiss BS, Kerndrup GB, Pedersen RK, Hasle H, Pallisgaard N. Contribution of multiparameter genetic analysis to the detection of genetic alterations in hematologic neoplasia. An evaluation of combining G-band analysis, spectral karyotyping, and multiplex reverse-transcription polymerase chain reaction (multiplex RT-PCR). Cancer Genet Cytogenet 2006;165:1-8. https://doi.org/10.1016/j.cancergencyto.2005.07.019
  10. Huh J and Chung W. A case of acute lymphoblastic leukemia with ider(9)(q10)t(9;22)(q34;q11.2). Korean J Lab Med 2006;26:223-6. https://doi.org/10.3343/kjlm.2006.26.3.223
  11. Diez-Martin JL, Dewald GW, Pierre RV. Possible cytogenetic distinction between lymphoid and myeloid blast crisis in chronic granulocytic leukemia. Am J Hematol 1988;27:194-203. https://doi.org/10.1002/ajh.2830270309
  12. Chan LC, Kwong YL, Liu HW, Chan TK, Todd D, Ching LM. Cytogenetic analysis of hematologic malignancies in Hong Kong. A study of 98 cases. Cancer Genet Cytogenet 1992;62:154-9. https://doi.org/10.1016/0165-4608(92)90255-7
  13. Anastasi J, Feng J, Le Beau MM, Larson RA, Rowley JD, Vardiman JW. The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia. Leukemia 1995;9:628-33.
  14. Choi GJ, Jeon DS, Chun HJ, Kim JR, Song HS, Lee JW. ider(9)(q10) t(9;22)(q34;q11.2) as secondary karyotypic aberration of chronic myelogeous leukemia. Korean J Clin Pathol 1999;19:266-70.
  15. Shearer BM, Flynn HC, Knudson RA, Ketterling RP. Interphase FISH to detect PBX1/E2A fusion resulting from the der(19)t(1;19) (q23;p13.3) or t(1;19)(q23;p13.3) in paediatric patients with acute lymphoblastic leukaemia. Br J Haematol 2005;129:45-52. https://doi.org/10.1111/j.1365-2141.2005.05415.x
  16. Shaffer LG, Slovak ML, et al. eds. ISCN 2009: an international system for human cytogenetic nomenclature (2009). Basel: Karger, 2009:59-83.
  17. Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, et al. Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Haematologica 2008;93:287-90. https://doi.org/10.3324/haematol.11891
  18. Faderl S, Estrov Z, Kantarjian HM, Thomas D, Cortes J, Manshouri T, et al. The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes $p15^{INK4b}/p16^{INK4a}/p14^{ARF}$ in patients with acute lymphoblastic leukemia. Cytokines Cell Mol Ther 1999;5:159-63.
  19. Bertin R, Acquaviva C, Mirebeau D, Guidal-Giroux C, Vilmer E, Cave H. CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 2003;37:44-57. https://doi.org/10.1002/gcc.10188
  20. Nowak NJ, Sait SN, Zeidan A, Deeb G, Gaile D, Liu S, et al. Recurrent deletion of 9q34 in adult normal karyotype precursor B-cell acute lymphoblastic leukemia. Cancer Genet Cytogenet 2010;199:15-20. https://doi.org/10.1016/j.cancergencyto.2010.01.014
  21. Barber KE, Harrison CJ, Broadfield ZJ, Stewart AR, Wright SL, Martineau M, et al. Molecular cytogenetic characterization of TCF3 (E2-A)/19p13.3 rearrangements in B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer 2007;46:478-86. https://doi.org/10.1002/gcc.20431
  22. Boomer T, Varella-Garcia M, McGavran L, Meltesen L, Olsen AS, Hunger SP. Detection of E2A translocations in leukemias via fluorescence in situ hybridization. Leukemia 2001;15:95-102. https://doi.org/10.1038/sj.leu.2401988
  23. Pui CH, Raimondi SC, Hancock ML, Rivera GK, Ribeiro RC, Mahmoud HH, et al. Immunologic, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(1;19) (q23;p13) or its derivative. J Clin Oncol 1994;12:2601-6.
  24. Griffin TC, Tomlinson GE, Raimondi SC, Sandoval C, Timmons CF, Rosenfield C, et al. Childhood acute lymphoblastic leukemia with both t(1;19) and t(9;22). Leukemia 1992;6:535-40.

Cited by

  1. Coexistence of Translocation(1,19) and the Philadelphia Chromosome in a Child's First Presentation of Chronic Myeloid Leukemia in Blast Crisis Treated with Dasatinib vol.28, pp.8, 2010, https://doi.org/10.3109/08880018.2011.615048